Stephen Polach

Background

About Stephen Polach

2018-Present: Study Coordinator: “Prospective, Multi-Site, Method Comparison Clinical Study of the ResistancePlus™ MG Diagnostic Accuracy in Detecting M. genitalium and Mutations Associated with Azithromycin Resistance”, Industry Funded, SpeeDx Pty. Ltd. Principal Investigator: Clair Kaplan, APRN. 2017-Present: Study Coordinator: “Clinical Utility Study to Evaluate: Clinical performance of cobas HPV for use on the cobas 6800/8800 Systems using cervical samples collected in PreservCyt for identification of high-grade cervical disease; and Clinical performance of CINtec PLUS Cytology on the VENTANA BenchMark ULTRA instrument for identification of high-grade cervical disease when used as a reflex test in high-risk HPV-positive women; cX8-HPV-435/D032425, Industry Funded, Roche Ventana. Principal Investigator: Clair Kaplan, APRN. 2015-Present: Study Coordinator: Performance of the cobas® HPV Test Using Samples Collected in SurePath™ Preservative Fluid™ for Identification of High-Grade Cervical Disease When Used as an Adjunct to Cervical Cytology in Women ≥30 Years and as a Primary Screening Test in Women ≥25 Years/COB-HPV-301. Industry Funded: Roche Molecular Systems. Principal Investigator: Timothy Spurrell, MD.